Dr. Reddy’s Laboratories has secured approval to manufacture and market Semaglutide, a crucial drug for weight loss and diabetes, marking a significant shift in India’s pharmaceutical landscape.
Tata Capital has settled a case with SEBI concerning the issuance of unlisted Cumulative Redeemable Preference Shares (CRPSs) and paid Rs 14.4 lakh. Learn more about this regulatory violation and how it affects Indian investors.
SEBI has given the final approval for the initial public offerings of four companies, including ICICI Prudential Asset Management Co. and Powerica Ltd. Here’s what investors need to know.
The government’s plan to sell up to 6% stake in Bank of Maharashtra via an offer-for-sale (OFS) is expected to increase public shareholding and improve the bank’s capital adequacy. Here’s what it means for investors.
Expert advice on top stocks like HUL, REC, GSK Pharma, KFin Tech, and SBI. Get the latest insights and updates from the Indian stock markets.
Gold prices have surged to Rs 1.33 lakh per 10 grams, driven by strong global cues and a weak US dollar. Here’s what’s driving the rally and how Indian investors can make the most of it.
Tilaknagar Industries has completed the acquisition of Imperial Blue business from Pernod Ricard India, making it a leading player in the Indian whisky market. Get the latest updates on this deal and its implications for the industry.
Foreign direct investment in India increased by 18% to $35.18 billion during April-September FY26, with the US more than doubling its inflows to $6.62 billion.
Overseas investors continue to sell Indian equities despite the Nifty 50 hitting a record high after the second-quarter GDP boost, with domestic institutions extending their buying streak.
SEBI is simplifying the offer document summary to encourage informed investor feedback and reduce reliance on unverified tips, aiming for a more transparent and efficient Indian stock market.